Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Z. Gülbas
BRENTUXIMAB VEDOTIN FOR RELAPSED HODGKIN LYMPHOMA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A RETROSPECTIVE STUDY OF THE EBMT LYMPHOMA WORKING PARTY
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
How to Select Donor, Stem Cell Source, and Conditioning Regimen for Haploidentical Transplants With Post-Transplant Cyclophosphamide for Lymphoma: A Report of the Ebmt LWP
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Brentuximab Vedotin Prior to Allogeneic Stem Cell Transplantation in Hodgkin Lymphoma: A Report From the EBMT Lymphoma Working Party
British Journal of Haematology
Hematology
Improving Outcomes After Allogeneic Hematopoietic Cell Transplantation for Hodgkin Lymphoma in the Brentuximab Vedotin Era
Bone Marrow Transplantation
Transplantation
Hematology
Brentuximab Vedotin Salvage Followed by Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in High Risk Relapsed Refractory Hodgkin Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Brentuximab Vedotin for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey
Annals of Hematology
Medicine
Hematology
Nivolumab for Relapsed/Refractory Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure – Polish Lymphoma Research Group Real-Life Experience
Acta Haematologica Polonica
Oncology
Hematology
Brentuximab Vedotin for Relapsed or Refractory CD30+ Hodgkin Lymphoma: A Multicenter Analysis From Asia
OncoTargets and Therapy
Oncology
Pharmacology
Functional Imaging Predicts Progression-Free Survival After Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in Relapsed/Refractory Hodgkin Lymphoma
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Cost-Effectiveness Analysis of Consolidation With Brentuximab Vedotin for High-Risk Hodgkin Lymphoma After Autologous Stem Cell Transplantation
Cancer
Cancer Research
Oncology
Patient-Reported Outcomes of Brentuximab Vedotin in Hodgkin Lymphoma and Anaplastic Large-Cell Lymphoma
OncoTargets and Therapy
Oncology
Pharmacology
